Literature DB >> 2042738

An agarose gel method for the determination of DNA interstrand crosslinking applicable to the measurement of the rate of total and "second-arm" crosslink reactions.

J A Hartley1, M D Berardini, R L Souhami.   

Abstract

A simple agarose gel electrophoresis method for the determination of DNA interstrand crosslinks is described. Following complete denaturation of 32P-end-labeled DNA the presence of an interstrand crosslink results in renaturation to double-stranded DNA. The single- and double-stranded bands separated on an agarose gel can be accurately quantitated by densitometry of the autoradiograph produced from the dried gel. The technique is particularly applicable to detailed time-course experiments of both total crosslink formation and, following removal of free drug, the "second-arm" of the crosslink reaction. The method is illustrated for a number of nitrogen mustard antitumor agents, showing how the moiety attached to a bifunctional reactive group can influence the extent and rate of crosslink formation and, in particular, the conversion of monoadducts to crosslinks. It is sensitive enough to follow the formation of crosslinks by slow and inefficient cross-linking agents such as busulfan which have not previously been measured by physical procedures.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2042738     DOI: 10.1016/0003-2697(91)90052-u

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  11 in total

1.  Backbone and benzoyl mustard carrying moiety modifies DNA interactions of distamycin analogues.

Authors:  A Ciucci; S Manzini; P Lombardi; F Arcamone
Journal:  Nucleic Acids Res       Date:  1996-01-15       Impact factor: 16.971

2.  Nitrogen mustard inhibits transcription and translation in a cell free system.

Authors:  A Masta; P J Gray; D R Phillips
Journal:  Nucleic Acids Res       Date:  1995-09-11       Impact factor: 16.971

3.  DNA crosslinking and biological activity of a hairpin polyamide-chlorambucil conjugate.

Authors:  Yong-Dong Wang; Jaroslaw Dziegielewski; Nicholas R Wurtz; Barbara Dziegielewska; Peter B Dervan; Terry A Beerman
Journal:  Nucleic Acids Res       Date:  2003-02-15       Impact factor: 16.971

4.  Thermal stability of DNA adducts induced by cyanomorpholinoadriamycin in vitro.

Authors:  C Cullinane; D R Phillips
Journal:  Nucleic Acids Res       Date:  1993-04-25       Impact factor: 16.971

5.  The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks.

Authors:  Laura J Niedernhofer; Hanny Odijk; Magda Budzowska; Ellen van Drunen; Alex Maas; Arjan F Theil; Jan de Wit; N G J Jaspers; H Berna Beverloo; Jan H J Hoeijmakers; Roland Kanaar
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

6.  Repair synthesis by human cell extracts in cisplatin-damaged DNA is preferentially determined by minor adducts.

Authors:  P Calsou; P Frit; B Salles
Journal:  Nucleic Acids Res       Date:  1992-12-11       Impact factor: 16.971

7.  DNA interstrand crosslinking and sequence selectivity of dimethanesulphonates.

Authors:  M Ponti; R L Souhami; B W Fox; J A Hartley
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

8.  Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9.

Authors:  S M Bailey; M D Wyatt; F Friedlos; J A Hartley; R J Knox; A D Lewis; P Workman
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 9.  From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs).

Authors:  Julia Mantaj; Paul J M Jackson; Khondaker M Rahman; David E Thurston
Journal:  Angew Chem Int Ed Engl       Date:  2016-11-15       Impact factor: 15.336

10.  The biological activity of cisplatin and dibromodulcitol in combination therapy.

Authors:  A Jeney; I Kovalszky; E Rásó; R E Durand; J Fürész; K Lapis
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.